Many prison inmates are forces to discontinue methadone treatment for opioid dependence as it remains widely unavailable behind bars in the United States. Now a new study by researchers from the Center for Prisoner Health and Human Rights, a collaboration of The Miriam Hospital and Brown University, offers some insight on the consequences of these mandatory withdrawal policies.
According to their research, published online by the Journal of Substance Abuse Treatment and appearing in the May/June issue, nearly half of the opioid-dependent individuals who participated in the study say concerns with forced methadone withdrawal discouraged them from seeking methadone therapy in the community after their release.
"Inmates are aware of these correctional methadone withdrawal policies and know they'll be forced to undergo this painful process again if they are re-arrested. It's not surprising that many reported that if they were incarcerated and forced into withdrawal, they would rather withdraw from heroin than from methadone, because it is over in days rather than weeks or longer," said senior author Josiah D. Rich, M.D., M.P.H., director of the Center for Prisoner Health and Human Rights, which is based at The Miriam Hospital.
He points out that methadone is one of the only medications that is routinely stopped upon incarceration. "This research highlights that what happens behind bars with methadone termination impacts our ability to give methadone, a proven treatment, to people in the community," he added."Given that opioid dependence causes major health and social issues, these correctional policies have serious implications."
For the past four decades, methadone has been the treatment of choice for opioid dependence, including heroin, and is on the World Health Organization's list of "Essential Medicines" that should be made available at all times by health systems to patients. This "anti-addictive" medication prevents withdrawal symptoms and drug cravings and blocks the euphoric effects of illicit opioids. Additionally, methadone therapy has been shown to reduce the risk of criminal activity, relapse, infectious disease transmission (including HIV and hepatitis) and overdose death.
However, in the United States, a significant proportion of people who are opioid dependent are not engaged in methadone replacement therapy. Rich says the majority of patients terminate treatment prematurely, often within the first year.
"If other evidence-based medicines like insulin therapy were routinely terminated or withdrawn from those who were incarcerated, we would hear about these serious lapses in care. They would likely garner some attention. But routine termination of methadone maintenance therapy has been occurring in the criminal justice system for decades and remains a little discussed and highly neglected issue," says lead author Jeannia J. Fu, Sc.B., a former researcher with The Miriam Hospital who is now affiliated with the Yale University School of Medicine.